Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

about

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

Item

http://www.wikidata.org/entity/Q47654494

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@en

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@nl

type

Item

label

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@en

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@nl

prefLabel

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@en

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@nl

P1476

Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.

@en

P2093

Ariel Schlaen

http://www.w3.org/2001/XMLSchema#string

Cristóbal Couto

http://www.w3.org/2001/XMLSchema#string

Debra Goldstein

http://www.w3.org/2001/XMLSchema#string

Erika Hurtado

http://www.w3.org/2001/XMLSchema#string

Marina Khoury

http://www.w3.org/2001/XMLSchema#string

Matilde Lopez

http://www.w3.org/2001/XMLSchema#string

Mercedes Frick

http://www.w3.org/2001/XMLSchema#string

P2860

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Immunopathology of the noninfectious posterior and intermediate uveitides.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease.

Biologics in the treatment of uveitis.

Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins.

TNF inhibition for ophthalmic indications: current status and outlook.

HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410.

Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09273948.2016.1236969

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27775450

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab